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Abstract
Objective—To determine if social support (SS) is associated with clinical outcomes during
antiviral therapy for chronic hepatitis C virus (HCV).
Methods—Data from 394 patients who participated in the prospective, longitudinal VIRAHEP-C
study were examined. VIRAHEP-C enrolled 401 adults with HCV to evaluate factors associated
with antiviral treatment response. Perceived SS was measured using the Medical Outcome Study
Social Support Survey (MOS-SSS) at baseline and treatment week 24. Scores were calculated as a
continuous variable ranging from 0%–100% with higher scores indicating greater support. Two SS
variables were created: (1) baseline SS (BL-SS) and (2) change in SS from baseline to treatment
week 24 (CH-SS). The primary endpoint was sustained virological response (SVR) six months
post-treatment. Intermediate outcomes included: symptom-reporting; virological response at
treatment week 24; medication adherence; neuropsychiatric adverse events; and dose reductions
and premature medication discontinuation. The relative risk of each outcome was estimated using
modified Poisson regression models or linear mixed models.
Results—BL-SS was relatively high (mean=79%). Overall, SS declined from baseline to
treatment week 24 (median change: −1.3%; p<0.01). Neither BL-SS nor CH-SS were associated
with SVR. However, BL-SS was associated with multiple symptoms (fatigue, headache,
irritability, aches/pains) during treatment, even after adjusting for baseline depression, which was
significantly associated with symptom-reporting.
Conclusions—SS was not directly associated with efficacy measures, such as SVR. However,
baseline SS predicted an increase in symptomatology over the course of antiviral therapy. Baseline
depression was also significantly associated with symptom-reporting.
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Introduction
Chronic hepatitis C virus (HCV) is the most common blood-borne infection, five times more
prevalent than HIV/AIDS, and affects 180 million people worldwide (1, 2). HCV can lead to
cirrhosis and liver cancer, resulting in 10,000 deaths per year in the United States alone, and
is the leading indication for liver transplantation (1, 3, 4). The individual and public health
burden of HCV is significant, and expected to increase in the next 20 years (4, 5).
Fortunately, curative treatment for HCV exists. The current treatment consists of
subcutaneous injections of pegylated interferon on a weekly basis, and taking oral ribavirin
twice daily (PEG/RBV) for up to 48 weeks(6). If patients have undetectable virus six
months post-treatment (known as a sustained virological response (SVR)), this “virological
cure” is associated with reduced risk for liver complications and improvements in quality of
life (1, 7–10).
Unfortunately many patients poorly tolerate the treatment regimen. This may be due to both
pre-existing biopsychosocial issues, as well as difficulty tolerating the side effects of PEG/
RBV treatment. Many individuals with HCV have co-existing medical conditions, reduced
quality of life, comorbid depression, anxiety, irritability, and perceive social stigmatization
due to HCV (11, 12). Moreover, PEG/RBV can cause numerous hematologic, physical, and
neuropsychiatric side effects, or can exacerbate pre-existing conditions, particularly
neuropsychiatric symptoms (7, 13–15).
In a previous investigation of depressive symptoms during antiviral therapy, Evon et al.
discovered that lower social support (SS) at baseline was associated with several markers of
depression at baseline. SS was also the strongest predictor of incident depression during
treatment. This relationship was interesting and indicated that perhaps, the relationship
between SS and other treatment outcomes warranted further investigation. The prevalence of
psychiatric and addiction disorders among HCV patients is high, and perceived social stigma
is common (12, 16). These factors can erode SS and theoretically undermine a successful
course of treatment (11, 17–19). Moreover, HIV literature suggests that SS may be
important to antiretroviral treatment outcomes, such that higher SS is associated with greater
likelihood of viral suppression (20). Based on this evidence, we hypothesized that SS could
impact the primary endpoint of PEG/RBV treatment, namely SVR, or could negatively
impact intermediate clinical outcomes such as medication-taking adherence or the ability to
tolerate side effects, which in turn, could impact SVR. To our knowledge, no study has
examined the effects of SS on clinical outcomes during antiviral treatment for HCV,
although it is widely assumed that adequate SS is an important component of treatment
success (11, 19, 21–24).
The large, prospective, longitudinal U.S. National Institutes of Health (NIH) funded study,
Viral Resistance to Antiviral Therapy of Chronic Hepatitis C (VIRAHEP-C), offers a unique
opportunity to investigate the impact of SS on clinical outcomes during antiviral treatment
for HCV, a treatment commonly associated with numerous adverse side effects and requires
a high rate of medication adherence (16, 17). While many indirect and mediating pathways
may exist, this initial investigation was designed to evaluate the direct relationship between
SS and primary and intermediate clinical outcomes. Given the association between SS and
depression in our previous study (25), we were also interested in assessing whether
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depression was significantly associated with any significant SS-clinical outcome
relationships. Thus, the specific aims of this study are as follows:
1. To evaluate whether baseline SS or the change in SS are associated with SVR, the
primary efficacy measure for antiviral therapy;
2. To determine if baseline SS or the change in SS are associated with the following
intermediate clinical outcomes which could impact SVR: symptom-reporting;
virological response at treatment week 24; medication-taking adherence;
neuropsychiatric adverse events; and dose reductions and premature medication
discontinuation secondary to neuropsychiatric adverse events; and
3. To examine the effects of depression on any statistically significant relationships
between SS and clinical outcomes.
Methods
Design
This study utilized the prospectively collected data from the NIH-funded study VIRAHEP-C
(26).VIRAHEP-C enrolled approximately equal numbers of African American (n=196) and
Caucasian (n=205) adults with chronic hepatitis C, genotype 1 infection at 8 U.S. medical
centers to evaluate factors associated with antiviral treatment response. Participants were
treated with PEG/RBV for up to 48 weeks, however those with detectable virus at week 24
were discontinued from therapy. Patients attended a baseline visit and then follow-up visits
for data collection at treatment weeks 2, 4, 8, 12 and monthly thereafter. All patients were
followed up to 6 months post-treatment to assess SVR. All subjects provided written
informed consent and the study was approved by the Institutional Review Boards of all
participating sites. Inclusion and exclusion criteria for the VIRAHEP-C parent study are
described elsewhere, but included: alcohol consumption of more than two drinks or
equivalent (>20 grams) per day; evidence of alcohol or drug abuse within 6 months prior to
screening; any current (within past 6 months) severe psychiatric disorder such as depression,
schizophrenia, bipolar illness, obsessive-compulsive disorder, severe anxiety, or personality
disorder; and a prior suicide attempt, hospitalization for psychiatric disease, or a period of
disability or impairment due to a psychiatric disease within the past 5 years. Patients whose
psychiatric disease was controlled by medication and deemed psychologically stable by the
investigator were eligible for participation (26). With the exception of the primary endpoint
(SVR), the current analyses were focused on the baseline to treatment week 24 time period,
since a large number of patients were discontinued from treatment at 24 weeks given
protocol-defined discontinuation rules for nonresponders. The initial sample was limited to
individuals with a baseline measure of SS (n=394).
Measures
Baseline Patient Characteristics—Age and depression were analyzed as continuous
variables; sex, race, marital status, educational level, employment status, health insurance,
alcohol consumption, smoking status, source of HCV infection, and liver disease (severe
fibrosis: Ishak fibrosis score ≥ 3) were analyzed as categorical variables.
Social Support—The Medical Outcome Study Social Support Survey (MOS SSS), a
reliable and validated 19-item self-report scale, was used to measure individuals’
perceptions of available SS (27). The survey consists of one overall SS index, and four
separate SS functional subscales measuring: (1) emotional/informational SS, (2) tangible SS,
(3) affectionate SS, and (4) positive social interaction. MOS SSS scores were calculated as a
continuous variable and analyzed on a transformed percentage scale (potential range of 0%–
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100%) with higher scores indicative of greater support (27). The MOS SSS also included a
single item to measure social integration (i.e., quantity of perceived available support) by
asking respondents to indicate the number of close friends or relatives with whom they “feel
at ease with and can talk to about what’s on your mind.” The MOS SSS was administered at
baseline and week 24 during VIRAHEPC. Two SS variables were created: (1) baseline SS
(BL-SS) and (2) change in SS from baseline to treatment week 24 (CH-SS). The planned
analyses employed the overall SS score, but post-hoc exploratory analyses explored the four
functional subscales and the single social integration item.
Depressive Symptoms—The Center for Epidemiologic Studies–Depression (CES-D)
scale, a 20-item self-report scale, was used to measure depressive symptoms at baseline and
weeks 4, 8, 12 and monthly thereafter (28). Items range from 0 (never) to 3 (almost always),
and total scores range from 0 to 60. For these analyses, we evaluated the baseline CES-D
total score as a continuous measure.
Primary Outcome
SVR was measured 24 weeks after the end of therapy, and defined as having an undetectable
HCV RNA (HCV RNA < 50 IU/mL) in serum by qualitative PCR; otherwise subjects (with
detectable or an indeterminate read 6 months after completion of PEG/RBV therapy) were
considered “non-SVR”.
Intermediate Outcomes
Symptom-Reporting: Six visual analog scales (VASs) were used to assess: (1) overall
symptomatology, (2) fatigue, (3) headaches, (4) muscle/joint aches and pains, (5) irritability,
and (6) depression. Symptom VASs were assessed at baseline and treatment weeks 1, 2, 4,
6, 8, and monthly thereafter. Participants marked a computerized line via a touch screen
which was converted to a continuous 0–10 scale with higher scores indicative of worse
symptoms. The VAS depression variable was analyzed in a prior publication and is not
described here (26).
Week 24 Virological Response: Subjects with an undetectable serum HCV RNA or an
indeterminate read at treatment week 24 were defined as “treatment week 24 responders”
and continued on treatment for another 24 weeks; subjects with detectable serum HCV RNA
at treatment week 24 were considered “treatment week 24 nonresponders” and were
discontinued from treatment.
Medication-taking Adherence (defined by the following two variables) was assessed with a
modified version of the Aids Clinical Trial Group Adherence Questionnaire at treatment
weeks 4, 12, and 24 for this analysis(29):
• Ribavirin Adherence: Subjects self-reported whether they had missed taking doses
of ribavirin for each of the 4 days preceding a clinic visit. If a subject reported
taking all 8 doses during those 4 days (i.e., 4 days multiplied by 2 doses per day)
for each of weeks 4, 12 and 24, they were considered fully adherent. If they missed
any dose, they were considered nonadherent.
• Peginterferon Adherence: Subjects reported whether they had missed taking any
PEG/RBV injections during the 4 weeks preceding a clinic visit. If a subject
reported taking all 4 weekly injections for each of weeks 4, 12 and 24, they were
considered fully adherent. If they missed any injections, they were considered
nonadherent.
Neuropsychiatric Adverse Events and Subsequent Dose Reductions (defined by the
following two variables) were assessed up to week 24 of the study:
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• Neuropsychiatric Adverse Events: any adverse event that was reported up to
treatment week 24, with the event specified as depression, other neuropsychiatric,
behavioral event/non-medical, or mental.
• Dose Reductions due to Neuropsychiatric Adverse Events: Defined as a reduction,
interruption, or discontinuation of either PEG or RBV due to a neuropsychiatric
adverse event (i.e., depression, other neuropsychiatric, behavioral event/non-
medical, or mental).
Premature Study Medication Discontinuations were assessed up to week 24 of the study.
They were defined as discontinuation of study medications up to treatment week 24 due to
patient intolerance, preference, nonadherence, or study participation discontinuation
(defined as discontinuation in the Virahep-C study due to patient withdrawal, loss to follow-
up, or refusal at any time).
Statistical analysis
Box and whisker plots were used to describe the distribution of BL-SS for the overall scales.
The median and interquartile range (IQR) of BL-SS and CH-SS across categorical patient
characteristic measures were calculated and differences assessed using a Wilcoxon rank sum
(two categories) or Kruskal-Wallis (more than two groups) test. Correlations between the SS
variables and continuous patient characteristic variables were assessed with Spearman’s
correlations. A Wilcoxon sign rank test was used to evaluate whether changes in SS from
baseline to treatment week 24 were significantly different than zero. Cohen’s d was used to
measure the effect sizes and assess their strength (30). Likelihood ratio tests were used to
evaluate change in VASs from baseline to treatment week 24.
A Poisson regression model with a robust variance estimator (31) was used to estimate the
relative risk (RR) of dichotomous clinical outcome measures (SVR; ribavirin medication
adherence; PegIFN medication adherence; neuropsychiatric adverse events; dose reductions
due to neuropsychiatric adverse events; premature study medication discontinuation; week
24 virologic response) and the two SS variables (BL-SS; CH-SS). The values of SS were
centered about their mean before inclusion in the model and a unit change of RR was
equivalent to a 10% change in the SS scale. To examine symptom VASs over time, a linear
mixed model was fit to each VAS including BL-SS, time, and BL-SS by time interaction
effects and a random subject effect with an unstructured covariance matrix. No formal
methods were used to correct for multiple testing, but to be conservative we set the level of
significance to α=0.01 for all analyses to reduce the chance of making a Type I error.
Post-hoc analyses were carried out for each of the four functional subscales using the same
methods: modified Poisson regression, regressing a BL-SS or CH-SS subscale onto each of
the clinical outcomes. For the primary analyses, we utilized the overall SS score because the
subscales were, for the most part, highly correlated with one another (all r’s > 0.64; p’s <
0.01 for baseline measures). This suggested high convergence and minimal discrimination
among the subscales, and that use of the overall subscale was both justifiable and
parsimonious. We analyzed the association between each of these subscale variables and the
clinical outcomes to elucidate any trends which may have been overlooked by using the
overall SS scale in the primary analyses. Similarly, we explored the relationship between
social integration and the outcomes. All analyses were carried out using SAS version 9.2
(Cary, NC).
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Patient Characteristics and Social Support
The characteristics of the overall population (N=401) who participated in the VIRAHEP-C
parent study are described elsewhere (26). Of the 394 participants who completed the
baseline SS measure and comprise the present study’s sample, the median age was 48 years
(range: 23 to 70 years), 65% were male, and 52% were Caucasian.
The distribution of BL-SS is presented in Figure 1. Baseline SS was relatively high in this
study population with 73% of patients having BL-SS scores greater than 70 (the average
MOS-SS score from the normative sample)(27). In those with week 24 SS data (n=257), the
median change in overall SS from baseline to treatment week 24 was - 1.3%. While this
decrement in SS was statistically significant (p<0.01), a Cohen’s d effect size indicated only
a small clinically significant effect size (d = −0.21).
The median and IQR of BL-SS and CH-SS across subject characteristics are presented in
Table 1. Employment, marital status, health insurance, and smoking status were associated
with BL-SS (all p-values <0.01). In general, participants who were married or in a
relationship, employed, nonsmokers, or did not have public health insurance, had the highest
levels of BL-SS, relative to comparison groups. Baseline CES-D was significantly and
negatively correlated with BL-SS (r= −0.46; p<0.01) but not with CH-SS (r=0.05; p=0.47).
No characteristics were associated with CH-SS.
Clinical Outcome Variables
Dichotomous clinical outcome variables were not different for participants with baseline
data only (n=394) versus those with both baseline and week 24 data (n=257); hence, only
percentages of the outcome variables at baseline are presented in Figure 2. Of the 34
individuals who discontinued medication early, 24 (71%) also discontinued the study. Fifty-
two percent of patients (n=204) had virological response at treatment week 24, and 40%
(n=158) achieved SVR. In the four days preceding each clinic visit, 27% (n=104) of patients
were nonadherent with taking ribavirin, and in the four weeks preceding each clinic visit,
only 8% (n=31) were nonadherent to administering their weekly interferon injection. While
23% of patients (n=92) developed neuropsychiatric adverse events, only 3% (n=11) and 9%
(n=34) required dose reductions or premature medication discontinuation, respectively, due
to neuropsychiatric adverse events.
The means of symptom VAS scores at each time point are plotted in Figure 3. All symptoms
significantly increased over the course of therapy from baseline to treatment week 24 (all p’s
> 0.0001).
Associations Between Social Support and Clinical Outcomes
BL-SS and CH-SS were not associated with SVR, the primary endpoint of antiviral
treatment (Table 2). The relationship between baseline SS and SVR was also nonsignificant
in a generalized estimating equation (GEE) model where we categorized baseline SS into
quartiles in order to look for nonlinear trends (data not shown). With regard to intermediate
endpoints, the relationship between CH-SS and PEG adherence (RR=0.98; 99% CI: 0.95,
1.001) approached statistical significance (p=0.012), but was in a counterintuitive direction,
such that as SS increased over time, PEG adherence decreased. BL-SS and CH-SS were not
associated with virological response, ribavirin adherence, neuropsychiatric adverse events,
or subsequent dose reductions or premature discontinuation of treatment due to such adverse
events.
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The relationships between BL-SS and symptom-reporting via VASs are reported in Table 3.
In unadjusted models, there was a main effect for the impact of BL-SS on overall symptoms,
aches/pains, irritability, and fatigue (p’s < 0.01). Despite low power availability to
adequately test for interaction effects, there was a suggestive indication of an interaction
between BL-SS and time, such that lower levels of BL-SS predicted worsening of overall
symptoms, aches/pains, and irritability over the first 24 weeks of antiviral therapy (p’s <
0.02). Since BL-SS and CES-D depression were correlated (r= −0.46) at baseline, we
assessed the impact of CES-D depression on these relationships in adjusted models.
Although the inclusion of baseline CES-D mitigated the main effect of BL-SS in these
models, the strength of the relationship (i.e., estimates) between BL-SS and symptoms over
time was unaffected (p’s < 0.02). Overall, CES-D depression was strongly associated with
all symptoms in adjusted models (all p’s < 0.001). A 10-point increase in the CES-D
depression score was associated with a 10% increase in symptoms.
Post-Hoc Analyses of Four Functional Subscales and Social Integration Item
In post-hoc analyses, we examined the association between the SS functional subscales
(emotional/informational, tangible, affectionate, and positive social interaction) and the
social integration item with all clinical outcomes to elucidate any relationships which may
have been overlooked by using the overall SS scale in the primary analyses. None of the
functional SS scales at baseline were associated with our primary endpoint, SVR. Change in
emotional/informational SS was significantly associated with PEG adherence (RR=0.98;
99% CI: 0.95, 0.998; p<0.01), such that adherence decreased as emotional/informational SS
increased. Change in affectionate SS was significantly associated with dose reductions due
to neuropsychiatric adverse events (RR=1.73; 99% CI: 1.04, 2.88; p <0.01), such that the
risk of dose reductions increased as affectionate SS increased. All other relationships with
virological response, ribavirin adherence, neuropsychiatric adverse events, and premature
treatment discontinuations, were not significant at α=0.01 (data not shown). Taken together
the number of post-hoc analyses conducted and the likelihood of Type 1 error contributing
to the two relationships significant at p=0.01, we concluded that, similar to the results with
the overall SS variable, no truly meaningful patterns emerged between any of the functional
support subscales and these clinical outcomes. With regard to social integration, at baseline,
patients (n=390) reported a median of 5.5 (IQR=3–10) close relatives or friends with whom
they felt at ease or could talk to. Social integration was not associated with SVR or any of
the dichotomous clinical outcomes (data not shown).
The relationships between the four functional SS subscales and the five VAS symptoms
were consistent with the primary analysis which employed the overall SS scale. In the
majority of post-hoc analyses, the main effect of the baseline functional subscale was
associated with the symptoms, and there was an increase in symptomatology over time.
When models were adjusted for baseline depression, the relationship between the main
effect of the functional subscale was mitigated, but the strength of the relationship between
symptoms and baseline functional subscales over time was unchanged (data not shown).
Discussion
The relationship between SS and mental and physical health has been evaluated in several
patient populations (32–34). Despite the physical, mental, social, and occupational
challenges that accompany HCV treatment, and the presumption that adequate SS is
important to treatment success, very few empirical investigations have examined the
relationship between SS and treatment outcomes during antiviral therapy for chronic
hepatitis C.
Evon et al. Page 7













The VIRAHEP-C study provided a unique opportunity to investigate the relationship
between SS and various clinical endpoints during treatment. In this study population, levels
of SS were rather high, with a mean SS score (mean=79) higher than the mean score
(mean=70) of the normative sample (27). Higher SS at baseline was associated with being
employed, married (or in a relationship), being a nonsmoker, and not having public health
insurance. Perhaps partially due to such high levels of support at baseline, we did not find
any evidence that patients’ SS impacts the hard endpoint of antiviral therapy: SVR.
With regard to intermediate clinical outcomes, baseline SS was inversely associated with
symptom-reporting, such that lower baseline SS (both the overall score and functional
subscale scores) was associated with higher symptoms of fatigue, aches/pains, irritability
and overall symptomatology. This suggests that patients who perceive satisfying levels of
SS tend to experience or report fewer symptoms during antiviral therapy. This is an
important finding since research demonstrates that adverse side effects are the primary
reason why treatment is discontinued prematurely (35, 36). We also discovered that baseline
depression, which was moderately correlated with SS, was significantly associated with
symptom-reporting. Baseline depression attenuated the main effect of SS on symptoms, but
did not considerably impact the relationship between baseline SS and overall symptoms,
aches/pains and irritability that occurred over the course of therapy. Thus, both SS and
depression are important predictors of symptom-reporting. At baseline, depression may be
of greater importance, but SS appears to continue to exert an effect on the perception of
worse symptomatology over time. These findings suggest that SS is important to how a
patient feels overall during treatment, and especially how they perceive aches/pains and
irritability in particular. Sufficient SS may function to buffer patients from depression,
which in turn, could positively affect treatment outcomes. This interpretation is consistent
with both the current HCV literature as well as the broader psychosocial literature which
suggests that social support improves health outcomes by buffering or protecting individuals
from psychological distress (32, 37, 38).
Baseline SS and change in SS, were not associated with ribavirin adherence,
neuropsychiatric adverse events, or dose reductions and premature study discontinuation due
to such adverse events. Although a borderline significant relationship was found between
change in SS and PEG adherence, this relationship was counterintuitive to expectations, and
we speculate, likely due to chance. Social integration (i.e., the quantity of one’s support
system) was unrelated to all outcomes of interest. Finally, our post-hoc analyses explored
four functional subscales (emotional/informational, tangible, affectionate, and positive social
interaction) and various clinical outcomes, which mirrored the primary analyses of overall
SS. Specifically, the functional scales were not related to SVR or other categorical clinical
outcomes, but they did predict levels of symptom-reporting.
In contrast to the results of this study, another study found that lower “social functioning”
was associated with lower rates of SVR in a sample of 74 participants with recently acquired
HCV infection, the majority of whom (85%) were injection drug users. (39). A subscale of a
questionnaire used to measure the effects of opiate treatment in injection drug users was
used to measure social functioning(40). This scale measures three constructs, only one of
which is social support: 1) social adjustment (i.e., proportion of time unemployed, number
of houses lived in over the last 6 months); 2) drug culture involvement (i.e., proportion of
acquaintances who are users); and social support measured as the number of close friends
(quantity not quality of SS). Given that this measure taps a broad range of social
functioning, it is not surprising that patients with worse social functioning (e.g., lack of
stable housing) had lower rates of SVR in their study. In the current study, we employed a
very specific measure of the quality of social support in a chronic HCV clinical trial
population, and found that participants had relatively high levels of SS at baseline, which
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may partially explain why SS was not related to SVR in our study. The major
methodological differences (e.g., patient populations, SS measurement) between the current
study and Dore’s study precludes any meaningful comparison, but rather highlights the
potential role of moderating variables that may explain associations between SS and SVR.
A few limitations of this study preclude generalizabilty of these findings to dissimilar patient
populations and clinical settings. This study occurred in the context of a large clinical study
where participants, clinicians, and the academic medical centers in which the data were
collected, may be strikingly different from other clinical settings in which HCV patients are
treated. These patients had to screen and qualify for a rigorous NIH study which employed
stringent exclusion criteria, including active substance abuse and unstable psychiatric
disease. Thus, selection bias may have indirectly excluded patients with low SS by virtue of
association with other patient characteristics (e.g., active drug use). In addition, these
patients had relatively high levels of support (mean=79.2%) compared to the general
medical populations on which the MOS-SSS was normed (mean=70%), and compared to the
HCV population at large (11, 39, 41–43). Therefore, these findings may not apply to
dissimilar patient populations, especially those who may suffer from significant substance
abuse or mental health comorbidities. Finally, the VIRAHEP-C research coordinators
received extensive training in side effect management and adherence enhancement
techniques(44), over and above that which is typical in most non-research clinical settings.
As such, study staff could have provided the distinct type of functional support that is
crucial to treatment success, thereby overshadowing, or rendering inconsequential, other
forms of support provided by patients’ family and friends. It is also possible that no
statistical relationship was found between SS and treatment outcomes, like SVR, because
the MOS-SSS instrument may have lacked the sensitivity or variability needed to capture
differences in outcome variables.
The results of this study have implications for clinicians who treat HCV. First, our findings
belie clinical experience and patients’ opinions that SS is critical to treatment success (21,
45, 46). However, this null relationship occurred in the context of patients having higher
levels of support, and minimal substance abuse or psychiatric issues, findings which may not
translate to patients with low levels of support or active addiction or psychiatric issues(39).
Although SS was not directly associated with SVR, it did seem to buffer patients from
experiencing multiple symptoms during treatment and perhaps help them cope better with
side effects. It remains unclear as to whether an increase in symptomatology affects
outcomes downstream, although studies indicate that adverse side effects are the primary
cause of early treatment discontinuation(7, 15). Stabilizing SS and depressive symptoms
prior to and during antiviral therapy may both be viable avenues to intervene to improve
symptom management.
The results of this study also have implications for future research. These findings may not
generalize to patients who receive treatment through standard (non-research) medical care.
As such it is critical to determine if these findings can be replicated in other ‘real world’
clinical settings with patients who are often ineligible for participation in research protocols
and may have lower levels of social support (e.g., individuals with psychiatric and addiction
issues). It is likely that SS is diminished in patients who perceive higher rates of social
stigma, and perhaps this leads to problems during standard treatment that are not observed
during rigorously-controlled research protocols. Second, follow-up studies should
investigate if an increase in symptomatology impacts treatment outcomes like SVR, as this
was not the focus of the present investigation. Finally, as numerous studies suggest that
depressive symptoms are related to negative events during antiviral treatment (25, 47, 48),
the development and testing of interventions to reduce depression is clearly a worthwhile
empirically-supported research endeavor.
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In conclusion, in this study cohort we found no evidence that baseline or change in SS has a
significant impact on SVR or other intermediate outcomes such as medication adherence,
adverse events, or premature medication discontinuation. However, lower baseline SS was
related to patients’ experience of worse symptoms during treatment. Depression appeared to
have an independent impact on symptom-reporting, over and above the impact of SS. The
relationship between SS and treatment outcomes needs to be viewed with caution until
future investigations can confirm or dispute these preliminary findings.
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Box and whisker plot displaying the distribution of the baseline (N=394) overall social
support scores and the four social support subscales. Median is represented by the dark line.
The box is representative of the interquartile range (IQR), and the small box with the ×
represents the mean. Data points outside of the whiskers are considered outliers. The median
(IQR) for the fives scores were as follows: Overall: 82.9 (68.4–97.0); Emotional/
Informational: 84.4 (68.8–100); Tangible: 81.3 (62.5–100); Affectionate: 91.7 (75–100);
Positive Social Interaction: 83.3 (58.3–100). The data are slightly negatively skewed. Most
participants (73%) reported baseline social support scores that were relatively high
compared to normative samples
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Percent categorical distributions of primary and intermediate clinical outcomes for entire
sample (N=394). Baseline data is presented as there were no differences with individuals
who were missing treatment week 24 data.
Note: SVR=Sustained Virologic Response; Tx24=Treatment Week 24 Virologic Response;
RBV=Ribavirin Adherence; PEG=Peglyated Interferon Adherence; AE=Neuropsychiatric
Adverse Events; DR=Dose Reductions Secondary to Neuropsychiatric Adverse Events;
Stop=Discontinued Study Medications Early
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Means of self-reported symptoms during HCV treatment using Visual Analog Scales. All
symptoms increased significantly over time from baseline through treatment week 24 (all
p’s < .0001).
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